Company intelligence / Profile preview

Bridge Health Biotech

Ownership: Private
Development stage: Other

Overview

Bridge Health Biotech owned the parental antibody for CLDN18.2, which was strategically acquired by I-Mab to secure intellectual property rights for givastomig, a CLDN18.2 x 4-1BB bispecific antibody showing promising Phase 1b results in gastric cancer.

Therapeutic areas: Oncology
Modalities: Bispecific monoclonal antibodyAntibody-drug conjugate
Industry: Biotech

Partnerships

I-MabABL Bio

Beyond the preview

Go deeper on Bridge Health Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bridge Health Biotech.

Explore the full profile